Clinical Trials Logo

Clinical Trial Details — Status: Terminated

Administrative data

NCT number NCT03435458
Other study ID # RC31/16/8911
Secondary ID
Status Terminated
Phase Phase 3
First received
Last updated
Start date June 26, 2020
Est. completion date February 2, 2023

Study information

Verified date May 2023
Source University Hospital, Toulouse
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The rate of obesity increases continuously in France as in many developing countries.The risk of cesarean delivery is increased in obese compared to normal-weight women and postpartum complications as infections, thromboembolic events and related maternal death, are more common among obese women who deliver by cesarean than both normal-weight women with caesarean deliveries and obese women with vaginal deliveries. Unfortunately, obesity is associated with a higher rate of failed induction requiring a cesarean delivery and especially in nulliparous. Methods of induction for obese women have to be improved to decrease the c-section rate but investigators should also be cautious on the type and dose of PG not to affect the neonatal wellbeing associated with uterine hyperstimulation. The aim of this study is to demonstrate the efficacy of the association of mechanical and pharmacological cervical ripening (balloon catheter plus 50 µg oral prostaglandin E1) versus pharmacological cervical ripening alone (50 µg oral prostaglandin E1) to reduce the rate of caesarean sections in nulliparous obese women.


Description:

The rate of obesity increases continuously in France as in many developing countries. In 2012, in the US, one third of all pregnant women were obese. The risk of cesarean delivery is increased in obese compared to normal-weight women and postpartum complications as infections, thromboembolic events and related maternal death, are more common among obese women who deliver by cesarean than both normal-weight women with caesarean deliveries and obese women with vaginal deliveries. Prevalence of post-term is increased in obese pregnant women and the rate of induction of labor is twice the rate of normal-weight women, 42% versus 23% in the 2010 French National Survey. Unfortunately, obesity is associated with a higher rate of failed induction requiring a cesarean delivery and especially in nulliparous. Methods of induction for obese women have to be improved to decrease the c-section rate but investigators should also be cautious on the type and dose of PG not to affect the neonatal wellbeing associated with uterine hyperstimulation. In a recent randomized clinical trial (RCT), the rate of c-section after labor induction in obese women was not increased in obese women compared to normal-weight women with balloon catheter but it was also increased with prostaglandin E2 (PGE2) and moreover with higher rate of uterine hyperstimulation. Recently, low dose of oral misoprostol (PGE1) has been showed to be the drug with the lowest rate of c-section after induction of labor in all women and balloon catheter to be associated with the lowest rate of hyperstimulation. Because safety of these two specific methods for induction of labor, a comparison 1 to 1 were done recently for induction of labor in singletons with comparable results. Very few studies have focused on induction of labor in obese women even if the rate of maternal and neonatal complications are higher. The efficacy of combining these two methods with different mechanism of induction have been showed recently but no study has been published today on obese women. Recently a trial have showed a shorter induction-delivery time with the combination (misoprostol-foley) for induction of labor in the whole population with less need of oxytocin during labor without more complications neither for the mother nor for the baby.An induction will be considered "failed" if at least 12 hours have elapsed since both rupture of membranes and use of a uterine stimulant and the patient remains in latent labor. The aim of this study is to demonstrate the efficacy of the association of mechanical and pharmacological cervical ripening (balloon catheter plus 50 µg oral prostaglandin E1) versus pharmacological cervical ripening alone (50 µg oral prostaglandin E1) to reduce the rate of caesarean sections in nulliparous obese women.


Recruitment information / eligibility

Status Terminated
Enrollment 429
Est. completion date February 2, 2023
Est. primary completion date February 2, 2023
Accepts healthy volunteers No
Gender Female
Age group 18 Years and older
Eligibility Inclusion Criteria: - female - pregestational BMI = 30 kg/m2 (weight/height2) - singleton pregnancy with cephalic presentation - nulliparous - = 36 weeks gestational age - decision of induction of labor - bishop score = 5 - = 3 uterine contractions / 10 min - = 18 years of age - personally signed and dated informed consent document - ability to comply with the requirement of the study - insurance coverage Exclusion Criteria: - deceleration on Fetal Heart Rate (FHR) - placenta praevia - bleeding - premature rupture of membrane - chorioamnionitis - allergy to prostaglandins - contraindication to ballon - active genital herpes infection - HIV infection - fetal serious congenital anomaly - patient subject to a legal protection order

Study Design


Related Conditions & MeSH terms


Intervention

Combination Product:
Balloon catheter + oral misoprostol
The pharmacological cervical ripening will be administered just after the balloon catheter insertion (after coming back in her room) and will consist of misoprostol 25 micrograms given orally (oral prostaglandin E1). The same dose will be given every 2 hours until beginning of labor with a maximum of 8 administrations.
Drug:
Oral misoprostol alone
Patients will receive a pharmacological cervical ripening alone that consist of Misoprostol 25 micrograms given orally (oral prostaglandin E1). The same dose will be given every 2 hours until beginning of labor with a maximum of 8 administrations.

Locations

Country Name City State
France CHU Bordeaux Bordeaux Nouvelle Aquitaine
France CHU Antoine Beclère Clamart Ile-de-France
France CHU Clermont-Ferrand Clermont-Ferrand Auvergne-Rhône-Alpes
France CHU Kremlin Bicêtre Le Kremlin-Bicêtre Ile-de-France
France CHRU Lille Lille Hauts-de-France
France Hôpital St Joseph Marseille Provence-Alpes-Côte d'Azur
France CHU Montpellier Montpellier
France CHU Nantes Nantes
France CHU Nimes Nîmes Occitanie
France Centre hospitalier St Joseph Paris Ile-de-France
France CHI Poissy Poissy Ile-de-France
France CHU Poitiers Poitiers
France CHU Saint Denis de la Reunion Saint-Denis La Réunion
France CHU St Etienne Saint-Étienne Auvergne-Rhône-Alpes
France CHU St Pierre de la Reunion Saint-Pierre La Réunion
France CHU de Toulouse Toulouse Midi-Pyrénées
France CHU Tours Tours Centre-Val De Loire
Martinique CHU Fort de France Fort de France

Sponsors (1)

Lead Sponsor Collaborator
University Hospital, Toulouse

Countries where clinical trial is conducted

France,  Martinique, 

References & Publications (3)

Battarbee AN, Palatnik A, Peress DA, Grobman WA. Association of Early Amniotomy After Foley Balloon Catheter Ripening and Duration of Nulliparous Labor Induction. Obstet Gynecol. 2016 Sep;128(3):592-597. doi: 10.1097/AOG.0000000000001563. — View Citation

Connolly KA, Kohari KS, Rekawek P, Smilen BS, Miller MR, Moshier E, Factor SH, Stone JL, Bianco AT. A randomized trial of Foley balloon induction of labor trial in nulliparas (FIAT-N). Am J Obstet Gynecol. 2016 Sep;215(3):392.e1-6. doi: 10.1016/j.ajog.2016.03.034. Epub 2016 Mar 24. — View Citation

McMaster K, Sanchez-Ramos L, Kaunitz AM. Evaluation of a Transcervical Foley Catheter as a Source of Infection: A Systematic Review and Meta-analysis. Obstet Gynecol. 2015 Sep;126(3):539-551. doi: 10.1097/AOG.0000000000001002. — View Citation

Outcome

Type Measure Description Time frame Safety issue
Primary Efficacy of the association of mechanical and low dose oral misoprostol compared to oral misoprostol alone, to reduce the rate of caesarean section of all indications in obese women. Assessed by the caesarean section occurrence whatever the indication (binary endpoint). Day 0 to day 2
Secondary Effectiveness criteria. Effectiveness criteria chosen for the cost-effectiveness analysis will be the caesarean section rate for all indications. Day 0 to day 2
Secondary Cost analysis. Cost estimates, for the construction of ICER, will be performed from the health insurance perspective.
Costs taken into account will be those related to the management of obese pregnant women during inpatient stays for the delivery in both arms (i.e. combining method vs. oral prostaglandin alone). They include the costs of initial hospitalization for delivery. The expenses incurred in the management of patients in each arm will be recorded over a the study follow-up.
Day 0 to day 2
Secondary Resources consumption collection. Resource consumption will be gathered prospectively in each arm, during the follow-up period using a bottom-up approach. Data will be collected from the Medical Information Departments of each center participating in the study for hospitalization costs. Day 0 to day 2
Secondary Costs valuation. Hospital stays will be valued from the French framework of pricing, the hospital Activity "Tarification à l'activité" (T2A). Hospital stays linked to the patient's care in each strategy will be valued from the French Diagnosis Related Group (DRGs). Day 0 to day 2
Secondary Cost-effectiveness analysis. A cost-effectiveness analysis will be performed from the health insurance perspective. An Incremental Cost Effectiveness Ratio (ICER) will be calculate to establish a link between costs and medical consequences, expressed in terms of rate of caesarian section rate, between the two strategies for labor induction. Day 0 to day 2
See also
  Status Clinical Trial Phase
Completed NCT00530439 - Lifestyle and Pregnancy: The Clinical Effect of Lifestyle Intervention During Pregnancy in Obese Women N/A
Not yet recruiting NCT06245083 - Evaluating Pyrroloquinoline Quinone (PQQ) for Improving Obese Pregnancy Outcomes Early Phase 1
Recruiting NCT03084120 - Effect of the Maternal Obesity and/or the By-pass on the Growth and the Nutritional Balance of the Child N/A
Recruiting NCT05207059 - Healthy Early Life Moments in Singapore N/A
Not yet recruiting NCT03913364 - Impact of B. Bifidum 900791 Intake on Breast Milk Characteristics of Obese Mothers N/A
Not yet recruiting NCT05986539 - Early Life Feeding Exposure and Infant Immune and Health Status.
Not yet recruiting NCT06179381 - Feeding the fAmiLy: the Intergenerational approaCh to fIght obesiTY (FACILITY)
Completed NCT05475951 - Gasdermin-D and Pannexin-1 in Pregnancy N/A
Active, not recruiting NCT04060381 - Myocardial Deformation Before and After Birth